Learn About Classical Hodgkin Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
City Of Hope - Duarte Main Campus
Alex Herrera is a Hematologist and a Hematologist Oncology provider in Duarte, CA. Dr. Herrera has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
City Of Hope Medical Foundation
Matthew Mei is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Mei is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.
Stanford Health Care
Ranjana Advani is an Oncologist and a Hematologist in Stanford, California. Dr. Advani has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. Her top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.
Summary: This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into in...
Summary: The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.